Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Extend NIP Period for MR Vaccines by 2 Years amid Shortage
March 13, 2025
- Chuikyo Rep Calls for Proper Use of Zepbound, Frets Expansion of Obesity Market
March 13, 2025
- Imdelltra, Balversa, 2 More New Drugs Skip March Listing
March 13, 2025
- Zepbound, Qalsody, and More New Drugs Set for Japan Listing on March 19
March 13, 2025
- MHLW to “Listen to Industry Opinions” in Policymaking around CEA: Minister
March 13, 2025
- CellCept Now Covered for Nephrotic Syndrome: MHLW
March 13, 2025
- Litfulo’s Price to Be Trimmed 3.8% in June after CEA
March 13, 2025
- Re-Priced Unprofitable Products Subject to Unit Price-Based Trades for 2 Years: MHLW
March 12, 2025
- Trerief and Nobelzin Newly Added to Elective Care Scheme; Allegra, Takepron Excluded
March 12, 2025
- Health Ministry Presents Proposal to Revise Priority Infectious Diseases
March 12, 2025
- Ishiba Hints at Reflecting Wage Hikes in Drug Pricing
March 11, 2025
- Stelara to Get 40.8% Price Cut on PMP Return, Januvia Over 26% in 2025 Revision
March 10, 2025
- Ishiba Flip-Flops on Copay Cap Hike, Drops Planned Raise in August
March 10, 2025
- NARO Miniaturizes Immunodeficient Pigs for Use in Drug R&D
March 10, 2025
- MHLW Unveils New List Prices for FY2025 Revision; Stelara, Januvia Hit by PMP Return
March 7, 2025
- Govt’s Regulatory Reform Panel Discusses Access to Clinical Trial Information
March 7, 2025
- Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
March 7, 2025
- New LDP Project Team Holds Hearing for Govt’s Startup Measures
March 6, 2025
- CAR-T Therapies Subject to Label Revision over Lymphoid Neoplasm Risk
March 6, 2025
- Safety-Related Label Revision Ordered for Trulicity, CP Inhibitors, and More
March 6, 2025
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…